Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Endo-Therapeutics history
Endo-Therapeutics company history timeline
Endo-Therapeutics, Inc. was established in 1992 in Safety Harbor, Florida.
In the fall of 1993 Dupont Merck decided to achieve some focus by establishing a subsidiary to serve as its generic division.
The division was formed in early 1994.
1994: The Endo name is revived as a generic division for the DuPont Merck joint venture.
1997: A management team acquires the DuPont Merck pain management drugs and the Endo name.
Endo posted a net profit of $201,000 in 1998, then a year later saw sales increase 28 percent to $138 million and net income to $3.26 million.
In November 1999 it reached an agreement to acquire Algos Pharmaceutical Corporation, a New Jersey-based biotech company that also specialized in pain management products.
Hind then developed a 5 percent lidocaine solution hand-sized patch, which gained FDA approval and which Endo began marketing as Lidoderm in 1999.
In October 2000, The Purdue Frederick Company sued Endo, alleging that Endo had infringed on patents relating to OxyContin by developing a generic form of the drug.
Sales grew another 43 percent in 2000 to $187.4 million.
Launched in the United States in June 2002.
The company suffered a setback in 2002 when MorphiDex failed to demonstrate in a late-stage clinical trial that it performed better than simple morphine in relieving pain.
In 2003 Endo added a pair of painkillers, paying $120 million to British biotech SkyePharma for the rights to Depomorphine and Propofol IDD-D, along with options on other products.
In 2004 Endo launched a pair of branded drugs: Frova and DepoDur, and along with continued strong growth in Lidoderm, the company was able to increase sales to $615.1 million.
Endo entered into a licensing agreement with Novartis to obtain the exclusive United States marketing rights for the prescription medicine Voltaren® Gel (diclofenac sodium topical gel) 1%. Voltaren Gel received regulatory approval in October 2007 from the United States Food and Drug Administration.
On March 23, 2009, Endo Pharmaceuticals successfully completed its acquisition of Indevus Pharmaceuticals, Inc.
On November 4, 2010, Penwest Pharmaceuticals becomes a wholly owned subsidiary of Endo Pharmaceuticals.
On June 20, 2011, American Medical Systems Inc (AMS) becomes a wholly owned subsidiary of Endo Pharmaceuticals.
December 2012, Endo’s board announces the retirement of President and CEO Dave Holveck.
In January 2013, Endo Corporate Headquarters moves from Chadds Ford to a newly constructed building at the Atwater Campus in Malvern, PA.
On February 28, 2014, Endo completed its acquisition of Paladin Labs, a leading Canada-based specialty pharmaceutical company.
On August 4, 2015, Endo completes its divestiture of AMS Men’s and Prostate Health Businesses to Boston Scientific.
On February 29, 2016, Endo announces the wind down of ASTORA Women’s Health Business (formerly AMS Women’s Health).
On July 3, 2017, Endo completes its divestiture of Litha Healthcare Group to Acino Pharma AG.
On November 7, 2018, Endo announces positive results from Phase 3 studies of collagenase clostridium histolyticum (CCH) in patients with cellulite.
On July 6, 2020, Endo announces that it received FDA approval of Qwo® (collagenase clostridium histolyticum-aaes).
© 2022 Endo International plc or one of its affiliates.
Rate how well Endo-Therapeutics lives up to its initial vision.
Endo-Therapeutics jobs
Do you work at Endo-Therapeutics?
Is Endo-Therapeutics' vision a big part of strategic planning?
Endo-Therapeutics history FAQs
Zippia gives an in-depth look into the details of Endo-Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Endo-Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Endo-Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Endo-Therapeutics. The data presented on this page does not represent the view of Endo-Therapeutics and its employees or that of Zippia.
Endo-Therapeutics may also be known as or be related to Endo-Therapeutics, Endo-Therapeutics Inc, Endo-Therapeutics, Inc. and Endo-therapeutics, Inc.